<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Castro J</submitter><funding>Generalitat de Catalunya, DGU</funding><funding>Universitat de Girona</funding><funding>Ministerio de Economia y Competitividad (MINECO) Spain</funding><pagination>2801</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9781652</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>14(12)</volume><pubmed_abstract>A family of dinuclear iron (II) compounds with iminopyridine-based ligands displays selective cytotoxic activity against cancer cell lines. All compounds have IC&lt;sub>50&lt;/sub> values 2-6 fold lower than that of cisplatin, and 30-90 fold lower than that of carboplatin for the tumor cell lines assayed. Comparing the IC&lt;sub>50&lt;/sub> values between tumor and non-tumor cell lines, the selectivity indexes range from 3.2 to 34, compound &lt;b>10, [Fe&lt;sub>2&lt;/sub>(4)&lt;sub>2&lt;/sub>(CH&lt;sub>3&lt;/sub>CN)&lt;sub>4&lt;/sub>](BF&lt;sub>4&lt;/sub>)&lt;sub>4&lt;/sub>&lt;/b>, showing the highest selectivity. Those compounds carrying substituents on the iminopyridine ring show the same cytotoxicity as those without substituents. However, the electronic effects of the substituents on position 6 may be important for the cytotoxicity of the</pubmed_abstract><journal>Pharmaceutics</journal><pubmed_title>Dinuclear Iron Complexes of Iminopyridine-Based Ligands as Selective Cytotoxins for Tumor Cells and Inhibitors of Cancer Cell Migration.</pubmed_title><pmcid>PMC9781652</pmcid><funding_grant_id>BIO2013-43517</funding_grant_id><funding_grant_id>SGR2014-70 and 2017 SGR 1720</funding_grant_id><funding_grant_id>MPCUdG2016-18 and MPCUdG2016/048</funding_grant_id><pubmed_authors>Marsal A</pubmed_authors><pubmed_authors>Vilanova M</pubmed_authors><pubmed_authors>Alonso-De Gennaro MJ</pubmed_authors><pubmed_authors>Romero I</pubmed_authors><pubmed_authors>Castro J</pubmed_authors><pubmed_authors>Bravo M</pubmed_authors><pubmed_authors>Claver C</pubmed_authors><pubmed_authors>Benito A</pubmed_authors><pubmed_authors>Martinez-Ferrate O</pubmed_authors><pubmed_authors>Alberti M</pubmed_authors><pubmed_authors>van Leeuwen PWNM</pubmed_authors></additional><is_claimable>false</is_claimable><name>Dinuclear Iron Complexes of Iminopyridine-Based Ligands as Selective Cytotoxins for Tumor Cells and Inhibitors of Cancer Cell Migration.</name><description>A family of dinuclear iron (II) compounds with iminopyridine-based ligands displays selective cytotoxic activity against cancer cell lines. All compounds have IC&lt;sub>50&lt;/sub> values 2-6 fold lower than that of cisplatin, and 30-90 fold lower than that of carboplatin for the tumor cell lines assayed. Comparing the IC&lt;sub>50&lt;/sub> values between tumor and non-tumor cell lines, the selectivity indexes range from 3.2 to 34, compound &lt;b>10, [Fe&lt;sub>2&lt;/sub>(4)&lt;sub>2&lt;/sub>(CH&lt;sub>3&lt;/sub>CN)&lt;sub>4&lt;/sub>](BF&lt;sub>4&lt;/sub>)&lt;sub>4&lt;/sub>&lt;/b>, showing the highest selectivity. Those compounds carrying substituents on the iminopyridine ring show the same cytotoxicity as those without substituents. However, the electronic effects of the substituents on position 6 may be important for the cytotoxicity of the</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Dec</publication><modification>2025-04-22T13:18:26.938Z</modification><creation>2025-04-06T00:38:09.742Z</creation></dates><accession>S-EPMC9781652</accession><cross_references><pubmed>36559294</pubmed><doi>10.3390/pharmaceutics14122801</doi></cross_references></HashMap>